A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms ABACUS
- 29 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.